Technical Analysis for BLCM - Bellicum Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 3.66 -0.81% -0.03
BLCM closed down 0.81 percent on Friday, March 22, 2019, on 1.48 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical BLCM trend table...

Date Alert Name Type % Chg
Mar 22 Calm After Storm Range Contraction 0.00%
Mar 22 Upper Bollinger Band Walk Strength 0.00%
Mar 22 Inside Day Range Contraction 0.00%
Mar 22 Overbought Stochastic Strength 0.00%
Mar 22 Upper Bollinger Band Touch Strength 0.00%
Mar 21 Stochastic Sell Signal Bearish -0.81%
Mar 21 Wide Range Bar Range Expansion -0.81%
Mar 21 Upper Bollinger Band Walk Strength -0.81%
Mar 21 Overbought Stochastic Strength -0.81%
Mar 21 Upper Bollinger Band Touch Strength -0.81%

Older signals for BLCM ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of various forms of cancer. Its lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The company is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Its preclinical product candidates include BPX-401, a chimeric antigen receptor (CAR-T) product candidate for the treatment of hematological cancers that express the CD19 antigen; BPX-601, a CAR-T product candidate for treating solid tumors overexpressing the prostate stem cell antigen; and BPX-701, a TCR product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Medicine Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatments Prostate Cancer Virotherapy Vaccination Melanoma Immunotherapies Cell Therapy Transplantation Kite Pharma Cancer Vaccine Hematological Cancers Chimeric Antigen Receptor Treatment Of Hematological Cancers Treatment Of Various Forms Of Cancer
Is BLCM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 10.26
52 Week Low 2.74
Average Volume 337,369
200-Day Moving Average 5.2288
50-Day Moving Average 3.3214
20-Day Moving Average 3.3535
10-Day Moving Average 3.5
Average True Range 0.251
ADX 19.99
+DI 27.6909
-DI 9.05
Chandelier Exit (Long, 3 ATRs ) 3.387
Chandelier Exit (Short, 3 ATRs ) 3.673
Upper Bollinger Band 3.8469
Lower Bollinger Band 2.8601
Percent B (%b) 0.81
BandWidth 29.425973
MACD Line 0.1138
MACD Signal Line 0.0481
MACD Histogram 0.0657
Fundamentals Value
Market Cap 121.61 Million
Num Shares 33.2 Million
EPS -2.94
Price-to-Earnings (P/E) Ratio -1.24
Price-to-Sales 975.18
Price-to-Book 2.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.98
Resistance 3 (R3) 4.01 3.93 3.92
Resistance 2 (R2) 3.93 3.85 3.92 3.90
Resistance 1 (R1) 3.80 3.80 3.76 3.77 3.89
Pivot Point 3.72 3.72 3.71 3.71 3.72
Support 1 (S1) 3.59 3.64 3.55 3.56 3.43
Support 2 (S2) 3.51 3.59 3.50 3.42
Support 3 (S3) 3.38 3.51 3.40
Support 4 (S4) 3.35